Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals, Inc. on $10.5M Reverse Merger and Financing

Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals, Inc. on $10.5M Reverse Merger and Financing

NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented DelMar Pharmaceuticals Inc. (OTC BB: DMPI), a company that focuses on the discovery and development of medicines with the potential to treat cancer patients who have been unsuccessful with modern targeted or biologic therapy, in a reverse merger and $10.5 million private placement financing which consists of a purchase price of $.80 per unit. Each unit consisted of a five-year warrant to purchase one share of common stock with an exercise price of $0.80. The Sichenzia Ross team was led by partner Gregory Sichenzia, David Manno and associate Jeff Cahlon.

Media Contact
pr@srf.law
212-930-9700

Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page
Sichenzia Ross Ference LLP
Click Here to Leave a Comment Below 0 comments

Leave a Reply: